Infantile hemangiomas (IHs) are the most common benign vascular tumors of childhood. They develop during the first few weeks of life and naturally progress by proliferating over several months before they involute and resolve; this renders them inconsequential in many cases, but sometimes IHs can have detrimental consequences on function and disfigurement. Hence, systemic propranolol has become a crucial element in IH management, alongside various other medical, procedural, and surgical options that aim to promote their quicker resolution and prevent and alleviate complications.
Keywords: Infantile hemangioma; Pediatric dermatology; Propranolol; Timolol; Vascular laser; Vascular neoplasm.
Copyright © 2022 Elsevier Inc. All rights reserved.